Anttila MI - Search Results

1

Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.

Heinonen EH, Anttila MI, Karnani HL, Nyman LM, Vuorinen JA, Pyykkö KA, Lammintausta RA. Heinonen EH, et al. Among authors: anttila mi. J Clin Pharmacol. 1997 Jul;37(7):602-9. doi: 10.1002/j.1552-4604.1997.tb04342.x. J Clin Pharmacol. 1997. PMID: 9243353 Clinical Trial.

2

Effect of concomitant hormone replacement therapy containing estradiol and levonorgestrel on the pharmacokinetics of selegiline.

Palovaara S, Anttila M, Nyman L, Laine K. Palovaara S, et al. Eur J Clin Pharmacol. 2002 Jul;58(4):259-63. doi: 10.1007/s00228-002-0469-y. Epub 2002 May 22. Eur J Clin Pharmacol. 2002. PMID: 12136372 Clinical Trial.

3

Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.

Heinonen EH, Anttila MI, Lammintausta RA. Heinonen EH, et al. Among authors: anttila mi. Clin Pharmacol Ther. 1994 Dec;56(6 Pt 2):742-9. doi: 10.1038/clpt.1994.204. Clin Pharmacol Ther. 1994. PMID: 7995016 Review.

4

Inhibition of platelet monoamine oxidase type B by selegiline.

Heinonen EH, Anttila MI, Nyman LM, Pyykkö KA, Vuorinen JA, Lammintausta RA. Heinonen EH, et al. Among authors: anttila mi. J Clin Pharmacol. 1997 Jul;37(7):597-601. doi: 10.1002/j.1552-4604.1997.tb04341.x. J Clin Pharmacol. 1997. PMID: 9243352 Clinical Trial.

5

Pharmacokinetics and metabolism of selegiline.

Heinonen EH, Myllylä V, Sotaniemi K, Lamintausta R, Salonen JS, Anttila M, Savijärvi M, Kotila M, Rinne UK. Heinonen EH, et al. Acta Neurol Scand Suppl. 1989;126:93-9. doi: 10.1111/j.1600-0404.1989.tb01788.x. Acta Neurol Scand Suppl. 1989. PMID: 2515726

6

Lack of adverse interactions between concomitantly administered selegiline and citalopram.

Laine K, Anttila M, Heinonen E, Helminen A, Huupponen R, Mäki-Ikola O, Reinikainen K, Scheinin M. Laine K, et al. Clin Neuropharmacol. 1997 Oct;20(5):419-33. doi: 10.1097/00002826-199710000-00006. Clin Neuropharmacol. 1997. PMID: 9331518 Clinical Trial.

7

CYP2D6 polymorphism is not crucial for the disposition of selegiline.

Scheinin H, Anttila M, Dahl ML, Karnani H, Nyman L, Taavitsainen P, Pelkonen O, Bertilsson L. Scheinin H, et al. Clin Pharmacol Ther. 1998 Oct;64(4):402-11. doi: 10.1016/S0009-9236(98)90071-6. Clin Pharmacol Ther. 1998. PMID: 9797797 Clinical Trial.

8

Dose linearity study of selegiline pharmacokinetics after oral administration: evidence for strong drug interaction with female sex steroids.

Laine K, Anttila M, Helminen A, Karnani H, Huupponen R. Laine K, et al. Br J Clin Pharmacol. 1999 Mar;47(3):249-54. doi: 10.1046/j.1365-2125.1999.00891.x. Br J Clin Pharmacol. 1999. PMID: 10215747 Free PMC article. Clinical Trial.

9

Multiple-dose pharmacokinetics of selegiline and desmethylselegiline suggest saturable tissue binding.

Laine K, Anttila M, Huupponen R, Mäki-Ikola O, Heinonen E. Laine K, et al. Clin Neuropharmacol. 2000 Jan-Feb;23(1):22-7. doi: 10.1097/00002826-200001000-00005. Clin Neuropharmacol. 2000. PMID: 10682227

10

Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.

Kivistö KT, Wang JS, Backman JT, Nyman L, Taavitsainen P, Anttila M, Neuvonen PJ. Kivistö KT, et al. Eur J Clin Pharmacol. 2001 Apr;57(1):37-42. doi: 10.1007/s002280100278. Eur J Clin Pharmacol. 2001. PMID: 11372588 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

95 results

Search Page